Compare Stocks: RLYB, UPB, NLTX, and LYEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LYEL Lyell Immunopharma	$14.37 +0.3%	$14.10	$11.47 ▼ $45.00	$350.90M	-0.04	118,275 shs	54,064 shs
NLTX Neoleukin Therapeutics	$38.60 +2.6%	$36.34	$2.03 ▼ $14.36	$362.76M	1.11	50,104 shs	205,633 shs
RLYB Rallybio	$16.92 +0.2%	$16.37	$3.67 ▼ $17.57	$89.61M	-0.85	15,187 shs	4,179 shs
UPB Upstream Bio	$6.01 -1.2%	$6.94	$5.77 ▼ $33.68	$333.01M	1.28	614,141 shs	642,852 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LYEL Lyell Immunopharma	+0.35%	-1.10%	+6.84%	+20.05%	+25.72%
NLTX Neoleukin Therapeutics	-1.96%	-0.66%	+9.30%	+41.98%	+91.50%
RLYB Rallybio	+0.24%	+0.65%	+4.83%	+6.08%	+266.23%
UPB Upstream Bio	-1.15%	-10.16%	-10.83%	-14.75%	-69.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LYEL Lyell Immunopharma	$14.37 +0.3%	$14.10	$11.47 ▼ $45.00	$350.90M	-0.04	118,275 shs	54,064 shs
NLTX Neoleukin Therapeutics	$38.60 +2.6%	$36.34	$2.03 ▼ $14.36	$362.76M	1.11	50,104 shs	205,633 shs
RLYB Rallybio	$16.92 +0.2%	$16.37	$3.67 ▼ $17.57	$89.61M	-0.85	15,187 shs	4,179 shs
UPB Upstream Bio	$6.01 -1.2%	$6.94	$5.77 ▼ $33.68	$333.01M	1.28	614,141 shs	642,852 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LYEL Lyell Immunopharma	+0.35%	-1.10%	+6.84%	+20.05%	+25.72%
NLTX Neoleukin Therapeutics	-1.96%	-0.66%	+9.30%	+41.98%	+91.50%
RLYB Rallybio	+0.24%	+0.65%	+4.83%	+6.08%	+266.23%
UPB Upstream Bio	-1.15%	-10.16%	-10.83%	-14.75%	-69.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LYEL Lyell Immunopharma	2.78	Moderate Buy	$40.86	184.32% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
RLYB Rallybio	2.00	Hold	N/A	N/A
UPB Upstream Bio	2.43	Hold	$29.67	393.62% Upside

Current Analyst Ratings Breakdown

Latest RLYB, UPB, NLTX, and LYEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/19/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	LYEL Lyell Immunopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/14/2026	LYEL Lyell Immunopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/6/2026	LYEL Lyell Immunopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
8/5/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/22/2026	LYEL Lyell Immunopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LYEL Lyell Immunopharma	$40K	8,801.63	N/A	N/A	$9.54 per share	1.51
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
RLYB Rallybio	$860K	104.47	N/A	N/A	$17.79 per share	0.95
UPB Upstream Bio	$2.85M	115.50	N/A	N/A	$4.95 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LYEL Lyell Immunopharma	-$274.45M	-$12.83	N/A	N/A	N/A	-920,285.25%	-91.62%	-70.50%	11/10/2026 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	N/A	N/A	N/A	-37.22%	-30.91%	N/A
RLYB Rallybio	-$8.98M	-$4.34	N/A	N/A	N/A	-911.07%	-40.53%	-38.13%	11/5/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest RLYB, UPB, NLTX, and LYEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/6/2026	Q2 2026	LYEL Lyell Immunopharma	-$1.94	-$1.9180	+$0.0220	-$1.92	$0.00 million	$0.00 million
8/6/2026	Q2 2026	RLYB Rallybio	-$1.28	-$1.09	+$0.19	$7.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LYEL Lyell Immunopharma	N/A	5.36	5.36
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
RLYB Rallybio	N/A	27.26	27.26
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LYEL Lyell Immunopharma	66.05%
NLTX Neoleukin Therapeutics	52.37%
RLYB Rallybio	90.34%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
LYEL Lyell Immunopharma	6.20%
NLTX Neoleukin Therapeutics	1.58%
RLYB Rallybio	10.30%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LYEL Lyell Immunopharma	270	24.50 million	22.99 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
RLYB Rallybio	40	5.31 million	4.76 million	Not Optionable
UPB Upstream Bio	38	54.77 million	45.76 million	N/A

RLYB, UPB, NLTX, and LYEL Headlines

Recent News About These Companies

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4 at 6:56 AM | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Upstream Bio (NASDAQ:UPB)

September 4 at 1:13 AM | americanbankingnews.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3 at 3:35 AM | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2 at 1:35 PM | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2 at 8:05 AM | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Target Price at $29.67

August 30, 2026 | americanbankingnews.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

August 14, 2026 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

August 14, 2026 | marketbeat.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

August 11, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, UPB, NLTX, and LYEL Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

$14.37 +0.05 (+0.35%)

As of 09/4/2026 04:00 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Neoleukin Therapeutics NASDAQ:NLTX

$38.60 +0.99 (+2.63%)

As of 09/4/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Rallybio NASDAQ:RLYB

$16.92 +0.04 (+0.24%)

As of 09/4/2026 04:00 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Upstream Bio NASDAQ:UPB

$6.01 -0.07 (-1.15%)

As of 09/4/2026 04:00 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLYB, UPB, NLTX, and LYEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLYB, UPB, NLTX, and LYEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLYB, UPB, NLTX, and LYEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, UPB, NLTX, and LYEL Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

Neoleukin Therapeutics NASDAQ:NLTX

Rallybio NASDAQ:RLYB

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLYB, UPB, NLTX, and LYEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLYB, UPB, NLTX, and LYEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLYB, UPB, NLTX, and LYEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, UPB, NLTX, and LYEL Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

Neoleukin Therapeutics NASDAQ:NLTX

Rallybio NASDAQ:RLYB

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools